Marathon Asset Management LLP boosted its stake in Johnson & Johnson (NYSE:JNJ) by 1.9% during the second quarter, Holdings Channel reports. The institutional investor owned 2,182,740 shares of the company’s stock after buying an additional 41,101 shares during the period. Johnson & Johnson accounts for approximately 5.6% of Marathon Asset Management LLP’s investment portfolio, making the stock its largest position. Marathon Asset Management LLP’s holdings in Johnson & Johnson were worth $264,759,000 at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of JNJ. Capital Asset Advisory Services LLC bought a new position in Johnson & Johnson during the second quarter worth approximately $202,000. Stelac Advisory Services LLC bought a new position in Johnson & Johnson during the first quarter worth approximately $192,000. Magnetar Financial LLC bought a new position in Johnson & Johnson during the first quarter worth approximately $223,000. Terra Nova Asset Management LLC bought a new position in Johnson & Johnson during the first quarter worth approximately $243,000. Finally, Arete Wealth Advisors LLC boosted its position in Johnson & Johnson by 10.8% in the first quarter. Arete Wealth Advisors LLC now owns 2,708 shares of the company’s stock worth $293,000 after buying an additional 265 shares during the period. 65.32% of the stock is owned by institutional investors and hedge funds.
Shares of Johnson & Johnson (NYSE:JNJ) traded down 0.54% during trading on Friday, reaching $118.81. The company’s stock had a trading volume of 4,772,980 shares. The firm has a market cap of $325.05 billion, a P/E ratio of 22.14 and a beta of 0.61. The stock’s 50 day moving average is $119.99 and its 200 day moving average is $116.25. Johnson & Johnson has a one year low of $89.90 and a one year high of $126.07.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, July 19th. The company reported $1.74 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.68 by $0.06. Johnson & Johnson had a return on equity of 24.70% and a net margin of 20.97%. The firm earned $18.50 billion during the quarter, compared to the consensus estimate of $17.98 billion. On average, equities analysts forecast that Johnson & Johnson will post $6.69 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd were given a $0.80 dividend. The ex-dividend date of this dividend was Friday, August 19th. This represents a $3.20 annualized dividend and a yield of 2.69%. Johnson & Johnson’s payout ratio is currently 60.15%.
A number of research analysts have recently commented on JNJ shares. Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $124.21 target price for the company in a report on Monday, August 22nd. Leerink Swann reissued an “outperform” rating and issued a $140.00 target price (up previously from $125.00) on shares of Johnson & Johnson in a report on Wednesday, July 20th. Zacks Investment Research cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Tuesday. BTIG Research reissued a “neutral” rating on shares of Johnson & Johnson in a report on Friday, June 3rd. Finally, RBC Capital Markets reissued an “outperform” rating and issued a $133.00 target price (up previously from $125.00) on shares of Johnson & Johnson in a report on Wednesday, July 20th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and ten have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $119.53.
In other Johnson & Johnson news, VP Dominic J. Caruso sold 41,146 shares of the business’s stock in a transaction that occurred on Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total value of $5,143,661.46. Following the completion of the sale, the vice president now owns 157,819 shares in the company, valued at $19,728,953.19. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Ronald A. Kapusta sold 2,935 shares of the business’s stock in a transaction that occurred on Friday, July 22nd. The shares were sold at an average price of $125.01, for a total value of $366,904.35. Following the completion of the sale, the chief accounting officer now owns 28,660 shares of the company’s stock, valued at approximately $3,582,786.60. The disclosure for this sale can be found here. 0.11% of the stock is owned by company insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.